Esketamine, a derivative of ketamine and an NMDA receptor antagonist, acts on glutamatergic neurotransmission to potentially disrupt pain signaling and neurogenic inflammation associated with cluster headaches. Its rapid-onset analgesic and neuromodulatory properties may provide acute relief by interrupting the neurological cascade that triggers cluster headache episodes, with potential for both immediate symptomatic management and prophylactic effects.